DMIIU Raises $500M in IPO, Eyes Pharma Target Amidst Growing Deficit

TL;DR

**DMIIU's cash is locked, but their burn rate is accelerating; find a deal or face the music.**

AI Summary

Drugs Made In America Acquisition II Corp. (DMIIU), a blank check company, reported a net loss of $46,158 for the three months ended September 30, 2025, and a net loss of $143,558 for the nine months ended September 30, 2025. This compares to a net loss of $41,684 for the period from inception (August 23, 2024) through September 30, 2024. The company successfully completed its Initial Public Offering (IPO) on September 26, 2025, raising $500,000,000 by issuing 50,000,000 units at $10.00 per unit. Simultaneously, it sold 1,200,000 Private Placement Units for $12,000,000 to its Sponsor and Cantor Fitzgerald & Co. As of September 30, 2025, $500,109,355 was held in the Trust Account, generating $109,355 in interest income for the nine-month period. Total assets surged to $501,005,711 from $138,064 at December 31, 2024, primarily due to the IPO proceeds. The company faces a significant deferred underwriting fee of $17,500,000 and an accumulated deficit of $17,282,546 as of September 30, 2025, up from $151,719 at December 31, 2024. The strategic outlook remains focused on identifying and completing a Business Combination within 24 months of the IPO.

Why It Matters

For investors, DMIIU's successful $500 million IPO provides substantial capital for its intended pharmaceutical industry acquisition, but the increasing accumulated deficit to $17.28 million signals rising operational costs before a deal. Employees and customers of potential target companies should note DMIIU's focus on the 'Drugs Made In America' theme, suggesting a strategic alignment with domestic pharmaceutical manufacturing. The broader market will watch to see if DMIIU can successfully identify and merge with a suitable target, as SPACs continue to be a significant force in M&A, particularly in specialized sectors. Competitive context is crucial, as many SPACs are vying for attractive targets in the healthcare and biotech space.

Risk Assessment

Risk Level: high — The company is a blank check company with no operations, generating a net loss of $143,558 for the nine months ended September 30, 2025, and an accumulated deficit of $17,282,546. It has a 24-month deadline from its September 26, 2025 IPO to complete a Business Combination, and failure to do so will result in liquidation, returning only the trust account funds to public shareholders, potentially less than the initial $10.00 per unit.

Analyst Insight

Investors should monitor DMIIU closely for any announcements regarding a potential Business Combination target, as this is the sole driver of value for a SPAC. Given the high risk associated with blank check companies and the 24-month deadline, consider this a speculative investment and be prepared for potential liquidation if a suitable target is not found.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$501,005,711

total Debt

$18,177,345

net Income

$ (143,558)

eps

N/A

gross Margin

N/A

cash Position

$315,087

revenue Growth

N/A

Key Numbers

• $500.0M — IPO Proceeds (Raised from 50,000,000 units at $10.00 each on September 26, 2025.)
• $12.0M — Private Placement Proceeds (From 1,200,000 units sold to Sponsor and Cantor Fitzgerald & Co.)
• $500.1M — Trust Account Balance (Cash and investments held as of September 30, 2025, for future Business Combination.)
• $17.5M — Deferred Underwriting Fee (Significant liability payable upon Business Combination completion.)
• $17.28M — Accumulated Deficit (Increased from $151,719 at December 31, 2024, reflecting operational costs.)
• $143,558 — Net Loss (9 months) (For the nine months ended September 30, 2025, indicating ongoing operational expenses.)
• $109,355 — Interest Income (Earned on cash and investments in Trust Account for the nine months ended September 30, 2025.)
• 65,575,000 — Ordinary Shares Outstanding (As of November 18, 2025, inclusive of shares in outstanding units.)
• 24 months — Combination Period (Deadline from IPO closing (September 26, 2025) to complete a Business Combination.)
• 80% — Fair Market Value Threshold (Minimum fair market value of target business relative to net assets in Trust Account.)

Key Players & Entities

• Drugs Made In America Acquisition II Corp. (company) — registrant
• Drugs Made In America Acquisition II LLC (company) — Sponsor and Private Placement Unit purchaser
• Cantor Fitzgerald & Co. (company) — underwriter and Private Placement Unit purchaser
• $500,000,000 (dollar_amount) — proceeds from Initial Public Offering
• $12,000,000 (dollar_amount) — gross proceeds from Private Placement Units
• $500,109,355 (dollar_amount) — cash and investments held in Trust Account as of September 30, 2025
• $17,500,000 (dollar_amount) — deferred underwriting fee payable
• $17,282,546 (dollar_amount) — accumulated deficit as of September 30, 2025
• September 26, 2025 (date) — closing date of Initial Public Offering
• 24 months (duration) — time limit to complete a Business Combination

FAQ

Risk Factors

• Deferred Underwriting Fee [high — financial]: A significant deferred underwriting fee of $17,500,000 is payable upon the completion of a Business Combination. This fee represents a substantial liability that will reduce the net proceeds available to the company and its shareholders upon a successful transaction.
• Business Combination Deadline [high — operational]: The company has a strict 24-month deadline from the IPO closing (September 26, 2025) to complete a Business Combination. Failure to do so will result in the cessation of operations, redemption of public shares, and dissolution, potentially leading to a loss for public shareholders.
• Accumulated Deficit [medium — financial]: The company has an accumulated deficit of $17,282,546 as of September 30, 2025, which has significantly increased from $151,719 at December 31, 2024. This indicates ongoing operational costs and expenses incurred prior to any revenue-generating business combination.
• Lack of Operating Revenue [medium — operational]: As a blank check company, DMIIU has not commenced any operations and will not generate operating revenues until after the completion of its initial Business Combination. All current income is non-operating interest income.
• Redemption of Public Shares [medium — financial]: Public shareholders have the right to redeem their shares if a Business Combination is not completed within the 24-month period. This could lead to a significant outflow of cash from the Trust Account, impacting the company's ability to fund a combination or return capital.
• Trust Account Investment Restrictions [low — regulatory]: Funds in the Trust Account are restricted to U.S. government treasury obligations with short maturities or money market funds investing in such obligations. This limits potential returns and exposes the company to interest rate risk.

Industry Context

Drugs Made In America Acquisition II Corp. operates within the Special Purpose Acquisition Company (SPAC) sector, which facilitates the public listing of private companies. The broader pharmaceutical and biotechnology industries, the intended focus for DMIIU's business combination, are characterized by high R&D costs, stringent regulatory oversight (FDA), patent cliffs, and significant M&A activity driven by the need for pipeline expansion and innovation.

Regulatory Implications

As a SPAC, DMIIU is subject to SEC regulations governing IPOs, disclosures, and business combinations. The target company will face extensive regulatory scrutiny from bodies like the FDA, impacting product development, marketing, and pricing. Compliance with securities laws is paramount throughout the business combination process.

What Investors Should Do

1. Monitor Business Combination Progress
2. Evaluate Target Company Due Diligence
3. Understand Redemption Rights
4. Assess Management Team's Execution Capability

Key Dates

• 2024-08-23: Company Inception — Marks the legal formation of Drugs Made In America Acquisition II Corp.
• 2025-09-24: Registration Statement Declared Effective — Indicates regulatory approval for the Initial Public Offering (IPO).
• 2025-09-26: Initial Public Offering (IPO) Consummation — Company raised $500 million, a critical step for funding future business combination activities.
• 2025-09-26: Private Placement Consummation — Raised an additional $12 million from Sponsor and Cantor Fitzgerald & Co., strengthening capital.
• 2025-09-30: Balance Sheet Date — Snapshot of the company's financial position post-IPO, showing significant increase in assets.
• 2027-09-25: End of Combination Period (Estimated) — The deadline for completing a Business Combination, after which dissolution procedures begin if unsuccessful.

Glossary

Blank Check Company

A company formed to raise capital through an initial public offering (IPO) for the purpose of acquiring an existing company, rather than operating a business itself. (DMIIU is a blank check company, meaning its primary activity is seeking a target for a business combination.)

Business Combination

The merger, share exchange, asset acquisition, or other similar transaction that a blank check company aims to complete with a target company. (The successful completion of a Business Combination is the primary objective and a critical event for DMIIU.)

Trust Account

A segregated account holding the proceeds from an IPO, typically invested in low-risk securities, to be used for a business combination or returned to shareholders if no combination is achieved. (DMIIU holds $500,109,355 in its Trust Account as of September 30, 2025, which is central to its operations and shareholder returns.)

Deferred Underwriting Fee

A portion of the underwriting commission that is not paid at the time of the IPO but is deferred and typically paid upon the completion of a business combination. (DMIIU has a significant deferred underwriting fee of $17,500,000, which is a liability contingent on a successful business combination.)

Accumulated Deficit

The cumulative net losses of a company since its inception, less any net income. (DMIIU has an accumulated deficit of $17,282,546, reflecting expenses incurred before generating revenue.)

Sponsor

The entity or individuals who organize and promote a special purpose acquisition company (SPAC), typically investing seed capital and receiving founder shares. (The Sponsor of DMIIU is involved in private placements and has forfeited shares, impacting the share structure.)

Units

A security offered in an IPO that typically consists of one ordinary share and a fraction of a warrant, or in the case of a SPAC, often includes shares that may be subject to redemption. (DMIIU sold 50,000,000 units in its IPO at $10.00 per unit.)

Year-Over-Year Comparison

This filing represents the first comprehensive financial reporting post-IPO for DMIIU. Compared to the period from inception (August 23, 2024) through September 30, 2024, the company has experienced a significant increase in total assets from $138,064 to $501,005,711, primarily due to the $500 million IPO proceeds. Operating expenses have also risen, reflected in a net loss of $143,558 for the nine months ended September 30, 2025, compared to a loss of $41,684 for the initial period. A major new liability, the deferred underwriting fee of $17,500,000, has emerged post-IPO.

Filing Documents

• ea0265078-10q_drugs2.htm (10-Q) — 448KB
• ea026507801ex31-1_drugs2.htm (EX-31.1) — 12KB
• ea026507801ex31-2_drugs2.htm (EX-31.2) — 12KB
• ea026507801ex32-1_drugs2.htm (EX-32.1) — 5KB
• ea026507801ex32-2_drugs2.htm (EX-32.2) — 5KB
• 0001213900-25-112095.txt ( ) — 3404KB
• dmaau-20250930.xsd (EX-101.SCH) — 39KB
• dmaau-20250930_cal.xml (EX-101.CAL) — 19KB
• dmaau-20250930_def.xml (EX-101.DEF) — 171KB
• dmaau-20250930_lab.xml (EX-101.LAB) — 298KB
• dmaau-20250930_pre.xml (EX-101.PRE) — 177KB
• ea0265078-10q_drugs2_htm.xml (XML) — 328KB

– Financial Information

Part I – Financial Information 1

Financial Statements

Item 1. Financial Statements 1 Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024 (Audited) 1 2 3 4

Notes to Financial Statements (Unaudited)

Notes to Financial Statements (Unaudited) 5

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 18

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 22

Controls and Procedures

Item 4. Controls and Procedures 22

– Other Information

Part II – Other Information 23

Legal Proceedings

Item 1. Legal Proceedings 23

Risk Factors

Item 1A. Risk Factors 23

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 23

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 23

Other Information

Item 5. Other Information 23

Exhibits

Item 6. Exhibits 24

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Interim Financial Statements

Item 1. Interim Financial Statements. DRUGS MADE IN AMERICA ACQUISITION II CORP. BALANCE SHEETS September 30, 2025 (UNAUDITED) December 31, 2024 (AUDITED) ASSETS Current Assets: Cash $ 315,087 $ 17,035 Due from Sponsor 566,269 — Prepaid expenses 15,000 42,580 Total Current Assets 896,356 59,615 Deferred offering costs — 78,449 Cash and investments held in Trust Account 500,109,355 — TOTAL ASSETS $ 501,005,711 $ 138,064 LIABILITIES AND SHAREHOLDERS' DEFICIT Current liabilities: Accrued expenses $ 5,843 $ — Accounts payable 4,592 — Accrued offering costs 113,162 4,683 Over-allotment liability 553,748 — Promissory note – related party — 250,100 Total Current Liabilities 677,345 254,783 Deferred underwriting fee payable 17,500,000 — Total Liabilities 18,177,345 254,783 Commitments and contingencies Ordinary shares subject to possible redemption, 50,000,000 shares at redemption value of $ 10.00 and $ 0 per share as of September 30, 2025 and December 31, 2024, respectively 500,109,355 — Shareholders' Deficit Preference shares, $ 0.0001 par value; 1,000,000 shares authorized; none issued or outstanding as of September 30, 2025 and December 31, 2024 — — Ordinary shares, $ 0.0001 par value; 220,000,000 shares authorized; 15,575,000 and 14,375,000 shares issued and outstanding, excluding 50,000,000 and 0 shares subject to redemption as of September 30, 2025 and December 31, 2024, respectively (1)(2) 1,557 1,437 Additional paid-in capital — 33,563 Accumulated deficit ( 17,282,546 ) ( 151,719 ) Total Shareholders' Deficit ( 17,280,989 ) ( 116,719 ) TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT $ 501,005,711 $ 138,064 (1) Includes an aggregate of up to 1,875,000 ordinary shares subject to surrender and forfeiture if the over-allotment option is not exercised in full by the underwriters (Note 5). (2) In February 2025, the sponsor surrendered and forfeited 18,847,722 ordinary

NOTES TO FINANCIAL STATEMENTS

NOTES TO FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Drugs Made In America Acquisition II Corp. (the "Company") is a blank check company newly incorporated in the Cayman Islands on August 23, 2024 . The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses (the "Business Combination"). The Company has not selected any Business Combination target and it has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any Business Combination target with respect to an initial Business Combination. Although the Company may acquire a business in any industry, it intends to focus on companies in the pharmaceutical industry. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of September 30, 2025, the Company had not commenced any operations. All activity for the period from August 23, 2024 (inception) through September 30, 2025 relates to the Company's formation, the initial public offering ("Initial Public Offering"), which is described below, and subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end. The registration statement for the Company's Initial Public Offering was declared effective on September 24, 2025. On September 26, 2025, the Company consummated the Initial Public Offering of 50,000,00

NOTES TO FINANCIAL STATEMENTS

NOTES TO FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) Following the closing of the Initial Public Offering on September 26, 2025, an amount of $ 500,000,000 ($ 10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Units was placed in a trust account ("Trust Account"), located in the United States and invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations and/or held as cash or cash items (including in demand deposit accounts), as determined by the Company, until the earlier of: (i) the completion of a Business Combination; (ii) the redemption of any Public Shares properly submitted in connection with a shareholder vote to amend the Company's amended and restated memorandum and articles of association (A) to modify the substance or timing of the Company's obligation to allow redemption in connection with its initial business combination or to redeem 100 % of the Public Shares if the Company does not complete its initial business combination within the Combination Period (as defined below) or (B) with respect to any other material provisions relating to shareholders' rights or pre-initial business combination activity; and (iii) the redemption of the Public Shares if the Company has not completed an initial business combination within the Combination Period, subject to applicable law, as described below. Transaction costs amounted to $ 28,357,609 , consisting of $ 10,000,000 of cash underwriting fee, $ 17,500,000 of deferred underwriting fee, and $ 857,609 of other offering costs. The Company will provide the holders of the outstanding Public Shares (the "Public Shareholders") with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business

NOTES TO FINANCIAL STATEMENTS

NOTES TO FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) The underwriters have agreed to waive their rights to their deferred underwriting commissions (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($ 10.00 ). The Company will have until 24 months from the closing of the Initial Public Offering to complete a Business Combination (the "Combination Period"). However, if the Company is unable to complete the initial Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account (net of funds withdrawn to pay taxes, if any, and up to $ 100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, which redemption will completely extinguish public shareholders' rights as shareholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and board of directors, liquidate and dissolve, subject, in each case, to the obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. In order to protect the amounts held in the Trust A

NOTES TO FINANCIAL STATEMENTS

NOTES TO FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying unaudited financial statements should be read in conjunction with the Company's Form 8-K as of September 26, 2025, as filed with the SEC on October 2, 2025, which contains the Company's audited balance sheet and notes thereto. The interim results for the three and nine months ended September 30, 2025 are not necessarily indicative of the results to be expected for the year ending December 31, 2025 or for any future periods. Emerging Growth Company The Company is an "emerging growth company," as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independe

View Full Filing

View this 10-Q filing on SEC EDGAR